Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 401–500 of 1,008
Fujii, T., Barzi, A., Bianchi, A. S., Cassingena, A., Siravegna, G., Karp, D. D., Piha-Paul, S. A., Subbiah, V., Tsimberidou, A. M., Huang, H. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2592 · Cited by 63
Self-citationSanaei, M., Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Shahrokh, S., Zali, M. R., & Bashash, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30655 · Cited by 62
“EGFR inhibitor therapy in the clinical treatment of patients with metastatic CRC (Douillard et al., 2013).”
BackgroundInfluentialCurcumin: A therapeutic strategy for colorectal cancer?
de Porras, V. R., Layos, L., & Martinez‐Balibrea, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.004 · Cited by 61
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 58
“Activating mutations in KRAS and NRAS have been reported in ∼40% and 8%–10% of CRCs, respectively [28, 43], causing resistance to anti-EGFR monoclonal antibodies [3, 43, 44] and conferring a negative prognosis [45, 46].”
BackgroundAdjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
Taïeb, J., Balogoun, R., Malicot, K. L., Tabernero, J. M., Mini, E., Folprecht, G., Laethem, J. V., Emile, J.-F., Mulot, C., Fratté, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw687 · Cited by 57
“Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.”
BackgroundSelf-citationNew Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 63
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 55
“A systematic review summarized several trials (COIN, PRIME, OPUS, and CRYSTAL) that addressed the question of whether the addition of an anti-EGFR agent to first-line chemotherapy improves outcomes amongst patients with extended RAS WT tumors.”
BackgroundInfluentialRAS Mutations in Colorectal Cancer
Douillard, J.-Y., Rong, A., & Sidhu, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1312697 · Cited by 54
Self-citationStrickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53
“For example, a recent report suggested that patients with KRAS exon 3 and 4 mutations, as well as those carrying variants in NRAS exon 2, 3, and 4, do not benefit of panitumumab treatment.(7) Although conclusive data are not available yet, preliminary findings suggest that these molecular alterations might also predic…”
BackgroundTowards improved drugs, combinations and patient selection
Schmoll, H., & Stein, A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.254 · Cited by 53
Hutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 60
“However, recent studies identified that tumours with a KRAS wild type (KRAS WT) and positive EGFR expression as measured by IHC was not predictive of anti-EGFR efficacy [20, 42, 50, 51].”
BackgroundTargeted therapies in gastroesophageal cancer
Kasper, S., & Schüler, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.009 · Cited by 54
“It was found that patients with colorectal cancers harbouring somatic mutations ofRAS oncogenes do not benefit from anti-EGFR antibody therapy [19,23].”
BackgroundTargeted Therapy of Colorectal Cancer
Seeber, A., & Gastl, G. A. (2016) · Oncology Research and Treatment · doi:10.1159/000453027 · Cited by 66
Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs
Lizarbe, M. A., Calle-Espinosa, J., Fernández-Lizarbe, E., Fernández‐Lizarbe, S., Robles-Ramos, M. Á., Olmo, N., & Turnay, J. (2017) · BioMed Research International · doi:10.1155/2017/7354260 · Cited by 57
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 59
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, J. H., Wu, C. S.-Y., & Bekaii‐Saab, T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.006 · Cited by 58
“In the phase 3 PRIME study, the addition of panitumumab to first-line FOLFOX in patients with RAS wild-type tumors improved survival compared with FOLFOX alone [59].”
Li, M. M., Cottrell, C. E., Pullambhatla, M., Roy, S., Temple‐Smolkin, R., Turner, S. A., Wang, K., Zhou, Y., & Vnencak‐Jones, C. L. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.11.002 · Cited by 60
Liu, X., George, G. C., Tsimberidou, A. M., Naing, A., Wheler, J. J., Kopetz, S., Fu, S., Piha-Paul, S. A., Eng, C., Falchook, G. S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1701-3 · Cited by 51
“[20–22] A recent meta-analysis has estimated the prevalence of KRAS exon 3 and 4 mutations to be 11 %, and NRAS mutations to be 9.”
Pietrantonio, F., Cremolini, C., Aprile, G., Lonardi, S., Orlandi, A., Mennitto, A., Berenato, R., Antoniotti, C., Casagrande, M., Marsico, V. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0171 · Cited by 57
Miroddi, M., Sterrantino, C., Simmonds, M. C., Caridi, L., Calapai, G., Phillips, R. S., & Stewart, L. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30280 · Cited by 55
Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., Ang, A. L., Bach, B. A., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3377 · Cited by 60
Tops, B. B. J., Normanno, N., Kurth, H. M., Amato, E., Mafficini, A., Rieber, N., Corre, D. L., Rachiglio, A. M., Reiman, A., Sheils, O. M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1015-5 · Cited by 53
“More recently, the value of selecting patients to be treated with targeted agents on the basis of specific molecular alterations of neoplastic cells has been acknowledged [2,3].”
BackgroundSakitani, K., Hirata, Y., Hikiba, Y., Hayakawa, Y., Ihara, S., Suzuki, H., Suzuki, N., Serizawa, T., Kinoshita, H., Sakamoto, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1789-5 · Cited by 54
“such as K-RAS mutations, is a major challenge [45, 46].”
BackgroundSalvatore, L., Aprile, G., Arnoldi, E., Aschele, C., Carnaghi, C., Cosimelli, M., Maiello, E., Normanno, N., Sciallero, S., Valvo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000147 · Cited by 53
Understanding next generation sequencing in oncology: A guide for oncologists
Moorcraft, S. Y., de Castro, D. G., & Walker, B. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.06.007 · Cited by 58
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Luo, H., & Xu, R.-H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3858 · Cited by 56
Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe
Dubbink, H. J., Deans, Z. C., Tops, B. B. J., van Kemenade, F. J., Koljenović, S., van Krieken, J. H., Blokx, W. A. M., Dinjens, W. N. M., & Groenen, P. J. T. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.004 · Cited by 53
“…yields a powerful instrument to enforce ISO 15189 accreditation by all laboratories, to make it mandatory to participate in nationwide EQA programs (Emile et al., 2013), and to actively monitor and maintain high quality molecular diagnostics if necessary by adequate penalties in case of poor…”
BackgroundInfluentialPOLE somatic mutations in advanced colorectal cancer
Guerra, J., Pinto, C., Pinto, D., Pinheiro, M., Silva, R., Peixoto, A., Rocha, P., Veiga, I., Santos, C., Santos, R. P., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1245 · Cited by 61
Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 52
Masuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., Shimada, K., Denda, T., Segawa, Y., Tanioka, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01042-w · Cited by 53
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65
Dasari, A. N., Sobrero, A. F., Yao, J. C., Yoshino, T., Schelman, W. R., Yang, Z., Chien, C., Kania, M. K., Tabernero, J. M., & Eng, C. (2021) · Future Oncology · doi:10.2217/fon-2021-0202 · Cited by 56
Self-citationEZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
Katona, B. W., Liu, Y., Ma, A., Jin, J. J., & Hua, X. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972776 · Cited by 54
“EGFR inhibitors have been well known to improve the survival of patients with KRAS wild type metastatic colon cancer, however these inhibitors have the opposite effect on KRAS mutant tumors, where they paradoxically decrease survival.(3) KRAS mutant colon cancers are notoriously difficult to treat, yet can represent u…”
BackgroundInfluentialAnti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
Feng, Q., Wei, Y., Chen, J., Chang, W., Ye, L., Zhu, D., & Xu, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4263 · Cited by 58
Management of resectable colorectal lung metastases
Moorcraft, S. Y., Ladas, G., Bowcock, A. M., & Chau, I. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9774-6 · Cited by 51
“with RAS mutations do not respond to panitumumab [34]) and therefore there is increasing interest in using circulating tumour DNA to potentially provide a more accurate representation of the mutational profile.”
High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., & Karayan-Tapon, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122015 · Cited by 50
“Nevertheless, nearly 35% of patients with WT RAS tumors do not respond to anti-EGFR treatment [3,4,6].”
BackgroundMartin, S. Z., Wagner, D., Hörner, N., Horst, D. A., Lang, H., Tagscherer, K. E., & Roth, W. (2019) · BMC Cancer · doi:10.1186/s12885-019-6270-4 · Cited by 60
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 57
Boeckx, N., Koukakis, R., de Beeck, K. O., Rolfo, C. D., Camp, G. V., Siena, S., Tabernero, J. M., Douillard, J., André, T., & Peeters, M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.03.005 · Cited by 53
Self-citationLiu, Z., Zhang, Y., Dang, Q., Wu, K., Jiao, D., Li, Z., Sun, Z., & Han, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632430 · Cited by 54
“Elegant efforts have demonstrated multifarious genomic alterations were critical to the prognosis and target therapy of CRC[31-35].”
BackgroundLahti, S. J., Xing, M., Zhang, D., Lee, J. J., Magnetta, M. J., & Kim, H. S. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.05.032 · Cited by 50
Chen, K.-H., Shao, Y.-Y., Chen, H.-M., Lin, Y.-L., Lin, Z.-Z., Lai, M.-S., Cheng, A.-L., & Yeh, K.-H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2358-2 · Cited by 37
“Patients were included in this study if they met the following criteria: [1] pathologically proven single primary CRC; [2] aged ≥ 18 years; [3] having known the cancer stage at diagnosis, according to the American Joint Committee on Cancer system, Sixth Edition; [4] having received standard chemotherapy (oxaliplatin,…”
MethodCohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T., Cutsem, E. V., Venook, A. P., Douillard, J., Heinemann, V., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab042 · Cited by 55
Self-citationAlonso‐Espinaco, V., Cuatrecasas, M., Alonso, V., Escudero, P., Mármol, M., Hörndler, C., Ortego, J., Gallego, R., Codony‐Servat, J., García‐Albéniz, X., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.019 · Cited by 48
Pecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A., Crocetti, S., Giglio, E., Giampieri, R., & Berardi, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00870-z · Cited by 49
Zhang, J., Chen, B., Li, H., Wang, Y., Liu, X., Wong, K. Y., Chan, W. N., Chan, A. K., Cheung, A. H. K., Leung, K. T., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6033 · Cited by 50
“Drug resistance and metastatic lesions develop frequently in CRC with KRAS/BRAF mutants [28,29].”
BackgroundCetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 57
“In the clinical management of mCRC patients, it is crucial to determine the presence of RAS mutations up front, as these are indicators predicting a poor response to the inhibition of EGFR [15,17,18].”
BackgroundSelf-citationTargeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 57
Sie, D., Snijders, P. J. F., Meijer, G. A., Doeleman, M., van Moorsel, M. I. H., Essen, H. F. H. V., Eijk, P. P., Grünberg, K., van Grieken, N. C. T., Thunnissen, E., et al. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0196-2 · Cited by 51
“, individualized, personalized or precision cancer medicine), the profiling of a tumor for the presence of specific somatic mutations has become crucial [3–7].”
Krens, L. L., Simkens, L. H. J., Baas, J. M., Koomen, E. R., Gelderblom, H. A. J., Punt, C. J. A., & Guchelaar, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112201 · Cited by 52
“Their benefit is restricted to patients with a KRAS exon 2 wild type tumor [5], which recently was further narrowed to RAS wildtype exon 2–4 tumors [6].”
BackgroundCirculating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis
Tóth, K., Barták, B. K., Tulassay, Z., & Molnar, B. A. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1132164 · Cited by 51
Targeted therapy and elderly people: A review
Daste, A., Chakiba, C., Domblides, C., Gross‐Goupil, M., Quivy, A., Ravaud, A., & Soubeyran, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.005 · Cited by 52
Jankú, F., Huang, H. J., Fujii, T., Shelton, D. N., Madwani, K., Fu, S., Tsimberidou, A. M., Piha-Paul, S. A., Wheler, J. J., Zinner, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw670 · Cited by 48
“prevalent in colorectal cancer, non–small cell lung cancer (NSCLC), and others and can be associated with less favorable prognosis or a lack of benefit from anti–epidermal growth factor receptor antibodies.[1-6] Furthermore, preclinical and early clinical data suggest that KRAS mutations can predict the response of ad…”
BackgroundKafatos, G., Niepel, D., Lowe, K., Jenkins-Anderson, S., Westhead, H., Garawin, T., Traugottová, Z., Bilalis, A., Molnar, E., Timar, J., et al. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0358 · Cited by 47
Self-citationYamashita, S., Chun, Y.-S., Kopetz, S., Maru, D. M., Conrad, C. H., Aloia, T. A., & Vauthey, J. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002245 · Cited by 48
Fumet, J.-D., Isambert, N., Hervieu, A., Zanetta, S., Guion, J.-F., Hennequin, A., Rederstorff, E., Bertaut, A., & Ghiringhelli, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000375 · Cited by 48
“1136/esmoopen-2018-000375 metastatic tumours without mutation of the KRAS and NRAS genes.(3) 9 10 In addition to chemotherapy, a promising approach of clinical development in CRC is immunotherapy.”
BackgroundRAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 48
“18 who should be tested The American Society for Clinical pathology, College of American Pathologists, Association for Molecular Pathology and the American Society of Clinical Oncology (ASCP/CAP/AMP/ASCO) issued joined guidelines for molecular testing in colorectal cancer in 2017.”
Garofano, F., Gonzalez-Carmona, M. A., Skowasch, D., Schmidt‐Wolf, R., Abramian, A., Hauser, S., Strassburg, C. P., & Schmidt‐Wolf, I. G. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174307 · Cited by 49
“For these patients, systemic chemotherapy with combinations of fluoropyrimidine, oxaliplatin, irinotecan in combination with EGFR antibodies or antiangiogenic antibodies is the standard of care in this palliative situation [46,47].”
BackgroundIsoniemi, H., Uutela, A., Nordin, A. J., Lantto, E., Kellokumpu, I., Ovissi, A., Kosunen, J., Kallio, R., Soveri, L., Salminen, T., et al. (2021) · British journal of surgery · doi:10.1093/bjs/znaa145 · Cited by 47
Jin, K., Chen, B., Liu, Y., Lan, H., & Yan, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01763-9 · Cited by 52
“Monoclonal antibodies for CRC therapy It has been shown that molecularly targeted agents are more efficient for improving OS and progression-free survival (PFS) of metastatic CRC [34].”
BackgroundKRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
“More recent studies have shown that non-exon 2 mutations are also associated with failure of response to EGFR therapy [67].”
BackgroundExploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy
Lin, C., Ng, H., Pan, W., Chen, H., Zhang, G., Bian, Z., Lü, A., & Yang, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125995 · Cited by 53
Screening for circulating RAS/RAF mutations by multiplex digital PCR
Andersen, R. F., & Jakobsen, A. K. M. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.007 · Cited by 51
Chen, J., Jin, Y., Zhai, Y., Qiong, Q., & Zhou, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10151 · Cited by 52
“There is evidence that treatment with anti-EGFR mAbs cetuximab or panitumumab improves the overall survival rate of RAS-WT patients [3-5].”
BackgroundBiomarker in Colorectal Cancer
Schirripa, M., & Lenz, H. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000190 · Cited by 49
“Conversely, in nonprespecified retrospective analyses of several phase III trials, BRAF V600E mutation failed to provide evidence for utility as predictive biomarkers because of the small number of patients and lack of statistical power.(78,79) Main results are summarized in Table 2.”
BackgroundMultidisciplinary approach of colorectal cancer liver metastases
Fiorentini, G., Sarti, D., Aliberti, C., Carandina, R., Mambrini, A., & Guadagni, S. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.190 · Cited by 52
The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies
Quirico, L., & Orso, F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.103 · Cited by 52
“RAS mutational status is used as a biomarker in colorectal cancer (CRC) to predict Epidermal Growth Factor Receptor (EGFR)-antibody response([42]).”
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 46
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Hohla, F., Winder, T., Greil, R., Rick, F. G., Block, N. L., & Schally, A. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6102 · Cited by 46
Oyanagi, H., Shimada, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Abe, K., Nakano, M., Kameyama, H., Takii, Y., Kawasaki, T., et al. (2019) · Histopathology · doi:10.1111/his.13805 · Cited by 50
Vivancos, A. P., Aranda, E., Benavides, M., Élez, E., Gómez‐España, M. A., Toledano‐Fonseca, M., Álvarez, M., Chica-Parrado, M. D. R., García‐Barberán, V., & Díaz‐Rubio, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-45616-y · Cited by 50
Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44
“For example, mutations in the KRAS gene are associated with resistance to anti-EGFR antibodies like cetuximab and panitumumab in CRC patients [15–17].”
BackgroundPrognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim, J.-Y., Jung, H. H., Do, I.-G., Bae, S., Lee, S. K., Kim, S. W., Lee, J. E., Nam, S. J., Ahn, J. S., Park, Y. H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2195-3 · Cited by 44
“Many tyrosine kinase inhibitors and monoclonal antibodies against EGFR and ERBB2 RTK have successfully been used as cancer drugs, for example cetuximab [33] and panitumumab [34] for EGFR overexpression, and afatinib [35] and dacomitinib as pan-HER inhibitors.”
BackgroundTreatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives
Holch, J. W., Stintzing, S., & Heinemann, V. (2016) · Visceral Medicine · doi:10.1159/000446052 · Cited by 50
Huxley, N., Crathorne, L., Varley‐Campbell, J., Tikhonova, I. A., Snowsill, T., Briscoe, S., Peters, J., Bond, M. L., Napier, M., & Hoyle, M. (2017) · Health Technology Assessment · doi:10.3310/hta21380 · Cited by 48
“Panitumumab plus FOLFOX4 compared with FOLFOX4 Douillard et al.(44) reported median PFS as 10.”
BackgroundMethodResultInfluentialA Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
Corti, G., Bartolini, A., Crisafulli, G., Novara, L., Rospo, G., Montone, M., Negrino, C., Mussolin, B., Buscarino, M., Isella, C., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.008 · Cited by 47
Self-citationLoree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0180 · Cited by 43
NK Cell-Based Immunotherapy in Colorectal Cancer
Chiesa, M. D., Setti, C., Giordano, C., Obino, V., Greppi, M., Pesce, S., Marcenaro, E., Rutigliani, M., Provinciali, N., Paleari, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10071033 · Cited by 47
Stefano, A. D., & Carlomagno, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 51
KRAS,NRASandBRAFmutations in Greek and Romanian patients with colorectal cancer: a cohort study
Negru, S. M., Papadopoulou, E., Apessos, A., Stănculeanu, D. L., Ciuleanu, E., Volovat, C. D., Croitoru, A. E., Kakolyris, S., Aravantinos, G., Ziras, N., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004652 · Cited by 49
“This result is comparable with the results obtained in other studies.(6) 23 24 There was no statistically significant difference in the mutation frequency between the two populations analysed (table 2).”
BackgroundResultInfluentialBencardino, K. B., Mauri, G., Amatu, A., Tosi, F., Bonazzina, E. F., Palmeri, L., Querques, M., Ravera, F., Menegotto, A., Boiani, E., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.001 · Cited by 47
Self-citationRAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Malapelle, U., Passiglia, F., Cremolini, C., Reale, M. L., Pepe, F., Pisapia, P., Avallone, A., Cortinovis, D. L., Stefano, A. D., Fassan, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.015 · Cited by 44
Pracht, M., Mogha, A., Lespagnol, A., Fautrel, A., Mouchet, N., Gall, F. L., Paumier, V., Lefeuvre‐Plesse, C., Rioux-Leclercq, N. C., Mosser, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12910 · Cited by 52
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Taniguchi, H., Yamazaki, K., Yoshino, T., Muro, K., Yatabe, Y., Watanabe, T., Ebi, H., Ochiai, A., Baba, E., & Tsuchihara, K. (2015) · Cancer Science · doi:10.1111/cas.12595 · Cited by 43
Prognostic impact of mutation profiling in patients with stage II and III colon cancer
Shen, Y., Han, X., Wang, J., Wang, S., Yang, H., Lu, S.-H., & Shi, Y. (2016) · Scientific Reports · doi:10.1038/srep24310 · Cited by 48
Xu, R., Shen, L., Wang, K.-M., Wu, G., Shi, C., Ding, K., Lin, L.-Z., Wang, J., Xiong, J., Wu, C., et al. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0263-y · Cited by 44
Mori, Y., Nyuya, A., Yasui, K., Toshima, T., Kawai, T., Taniguchi, F., Kimura, K., Inada, R., Nishizaki, M., Haraga, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24735 · Cited by 42
Rachiglio, A. M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., De Luca, A., Carotenuto, M., Frezzetti, D., Martinelli, E., et al. (2019) · Cancers · doi:10.3390/cancers11060859 · Cited by 43
“agents that block the epidermal growth factor receptor (EGFR), such as the anti-EGFR monoclonal antibodies (MoAbs) cetuximab or panitumumab, are an effective therapeutic option in combination with chemotherapy in mCRC patients [2,3].”
BackgroundYe, P., Cai, P., Xie, J., & Wei, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248775 · Cited by 47
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 51
Erve, I. V. ’., Medina, J. E., Leal, A., Papp, E., Phallen, J. A., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2538 · Cited by 49
“…Systemic treatment with therapeutic mAb directed against EGFR can be offered to patients with mCRC, provided that no mutation in either KRAS , NRAS ,or BRAF ispresentandthelocationoftheprimary tumor is left sided (17, 18), but it has shown to be effective in only a limited percentage (10% – 20”
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
“False-negative results of RAS testing, which may be attributed to the failure of tumor cell dissection or poor performance of DNA assays, possess significant risks for the patient, as EGFR inhibition in RAS-mutated tumors may facilitate the disease’s progression [39].”
BackgroundGenotype-based clinical trials in cardiovascular disease
Pereira, N. L., Sargent, D. J., Farkouh, M. E., & Rihal, C. S. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.64 · Cited by 46
Tack, V., Ligtenberg, M. J. L., Tembuyser, L., Normanno, N., Borght, S. V., van Krieken, J. H., & Dequeker, E. M. C. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0382 · Cited by 46
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
“[59,60] Expanded analysis showed that mutations in KRAS exons 3 and 4 as well as NRAS exons 1, 2, 3 and 4 abolished any benefit from cetuximab [61] or panitumumab.”
BackgroundSelf-citationCutsem, E. V., Prenen, H., D’Haens, G., Bennouna, J., Carrato, A., Ducreux, M. P., Bouché, O., Sobrero, A. F., Latini, L., Staines, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv286 · Cited by 44
“Notwithstanding the obvious pitfalls of inter-trial comparisons, the median PFS observed with nintedanib plus mFOLFOX6 in this study of an unselected mCRC patient population are comparable with data for EGFR inhibitors cetuximab and panitumumab plus FOLFOX in RAS wild-type mCRC patients [16, 17].”
ResultGleeson, F. C., Kipp, B. R., Voss, J. S., Campion, M. B., Minot, D. M., Tu, Z. J., Klee, E. W., Sciallis, A. P., Graham, R. P., Lazaridis, K. N., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpu3j7fgayqbrl · Cited by 42
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.